Prof. PeptideProf. Peptide

October 17, 2026

Two October Papers Look at What Is Reported After Use of Unapproved Retatrutide

Two peer-reviewed papers published in October examine what happens outside the clinical trials of retatrutide, which is investigational and unapproved. One is a JAMA Network Open analysis of symptoms that social media users report. The other is a BMJ Case Reports account of a hospital admission. Both describe products whose identity, purity and dose could not be verified.

On this page
  1. 1.JAMA Network Open: self-reported symptoms
  2. 2.What the authors say the data cannot show
  3. 3.BMJ Case Reports: one admission
  4. 4.How this fits with the trial record
  5. 5.What this is, and isn’t
  6. 6.Sources

Reports, not rates. Neither paper can say how often a symptom occurs, whether retatrutide caused it, or what any product contained. Both authors say so. The figures below describe what people wrote or what one patient was told, and they should not be read as incidence or as comparisons with trial results.

JAMA Network Open: self-reported symptoms

The research letter, by University of Pennsylvania and Boston Children’s Hospital authors, was published online October 14, 2026. It analyzed 148,640 retatrutide-related Reddit posts and comments from 38,936 users across 27 communities, dated from May 2021 to December 2025. Large language models identified posts describing current use and extracted symptoms, which were mapped to standard medical terminology; the authors validated 100 posts manually.

A classifier flagged 13,589 users who reported current use. Of those, 7,823 (57.6%) had at least one symptom term left after weight-loss and appetite-suppression terms were excluded, and they form the denominator. The most common terms were increased appetite (17.1% of those users), fatigue (15.2%), increased energy (12.4%) and nausea (11.6%), followed by food craving, insomnia and increased heart rate (4.8%). The authors note gastrointestinal symptoms were “common but not dominant,” unlike in phase 2 trials and approved GLP-1 drugs, and that reports of increased appetite were “unexpected.”

What the authors say the data cannot show

The paper describes its findings as “hypothesis-generating.” It states that product identity, purity, dose, route, duration, concomitant medications and medical history “cannot be verified,” and that the analysis “cannot assess incidence, causality, dose-response, or comparative safety.” It lists alternative explanations for the reports, including product or dose variability, concurrent use of several unapproved peptides, reconstitution practices and misattribution, and notes that adverse events may be preferentially reported on social media. The authors suggest clinicians screen non-judgmentally for nonapproved peptide use and that adverse events be reported to the FDA’s MedWatch system.

BMJ Case Reports: one admission

A case report published October 7, 2026 describes a woman in her mid-20s admitted with five days of persistent nausea, repeated vomiting, loose stools and reduced oral intake. Blood tests, urinalysis, abdominal ultrasonography and cerebral MRI found no alternative cause, and symptoms persisted despite intravenous fluids and three anti-nausea drugs. A repeated exposure history then established four once-weekly, dose-escalated subcutaneous injections of an unverified product reported to contain retatrutide, given in a wellness setting by a self-described life coach without medical qualification. She did not regard the injections as medication.

Symptoms improved two days after admission and resolved within a week. The report assigns a Naranjo score of 7, which it classes as probable causality, and concludes that clinicians should ask explicitly about injections, peptides, research chemicals and online products. As a single case with an unverified product, it cannot show that retatrutide was the cause, and the report’s own causality score is an assessment, not proof.

How this fits with the trial record

The trial literature for retatrutide, including TRIUMPH-2 and TRIUMPH-1, describes adverse events in supervised participants receiving a defined product. These two papers describe reports from people who obtained products outside any supervised setting. They answer different questions. A JAMA Medical News article of October 9, titled “Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain,” also covers the online market; only its summary was available for this article, so its content is not described here.

The legal side of that market is in Prof. Peptide’s report on Lilly’s August lawsuits against retatrutide sellers, which are allegations that have not been decided.

What this is, and isn’t

This is reporting on two published papers, read from the research letter’s full text and the case report’s abstract. The first is an observational analysis of public posts; the second is a single case. Neither establishes that retatrutide causes any symptom, and neither evaluates any particular product or seller. Retatrutide is investigational and is not approved for human use anywhere. Nothing here is medical advice or a usage recommendation.

Sources

This article is for informational and educational purposes only and does not constitute medical advice. It reports two published papers; their findings are reports and a single case, not incidence or causation, and the products involved were not verified. It makes no safety, efficacy, dosing, or approval claim about any compound. Retatrutide is an investigational compound that is not approved for human use in any jurisdiction. All research compounds referenced are for laboratory use only and are not for human consumption.